GLP-1 Medications Safety Checklist: Red Flags and What to Verify [2026]

This article is for informational purposes only and does not constitute medical advice. Always consult a board-certified physician before starting, stopping, or changing any medication. Individual results vary, and GLP-1 medications carry risks that require professional medical supervision.

The GLP-1 Daily may earn a commission from qualifying purchases through affiliate links. This does not influence our editorial recommendations.

Quick Answer

Verify your provider's credentials — a licensed physician or NP should evaluate your full medical history, run baseline labs, and monitor you throughout treatment. Walk away from any provider who prescribes without a proper intake.
Compounded GLP-1s carry real risks — the FDA received over 1,150 adverse event reports tied to compounded semaglutide and tirzepatide as of late 2025, including hospitalizations and deaths.
Watch for red flags at every stage — suspicious pricing, no dose titration schedule, missing ingredient verification, and lack of follow-up appointments all signal a provider cutting corners.
Know the serious side effects — while most GLP-1 side effects are mild GI issues, rare but serious complications like pancreatitis, gallbladder disease, and pulmonary aspiration risk during surgery require immediate attention.

Why a Safety Checklist Matters More Than Ever in 2026

The GLP-1 market in 2026 is enormous. Tens of millions of Americans have now tried semaglutide or tirzepatide in some form. Medications like Ozempic, Wegovy, Mounjaro, and Zepbound have become household names. That popularity has brought a flood of new providers — telehealth startups, med spas, compounding pharmacies, and wellness clinics — all competing for patients.

Some of them are excellent. Many are not.

The FDA sent 30 warning letters in February 2026 alone, targeting telehealth companies and online wellness clinics making false or misleading claims about compounded GLP-1 medications. That wave of enforcement came after the agency had already received 1,150 adverse event reports tied to compounded versions of these drugs, including hospitalizations and some deaths.

Here's the problem: the average patient can't easily tell the difference between a legitimate, well-run telehealth program and a fly-by-night operation selling underdosed (or overdosed) compounded semaglutide with zero medical oversight. The branding looks the same. The websites are polished. The Instagram ads promise the same results.

This checklist exists to fix that. Whether you're considering a brand-name GLP-1 from your primary care doctor or a compounded version from a telehealth platform, there are specific things you should verify at every stage — before you start, during treatment, and if something feels wrong. If you're brand new to these medications, start with our beginner's guide and come back here once you've got the basics down.

Think of this as your pre-flight checklist. Pilots don't skip it because they've flown a thousand times. You shouldn't skip it because a provider seems professional on their website.

The stakes are your health. Let's make sure you're protected.

Red Flags Before You Start: Vetting Your Provider

The first and most important safety check happens before a single injection. The provider you choose determines almost everything — the quality of your medication, the appropriateness of your dose, your monitoring schedule, and whether anyone is watching for complications.

Credential Verification

Your prescriber should be a licensed MD, DO, NP, or PA. Not a "wellness coach." Not a "health consultant." Check their license through your state medical board's online portal. It takes two minutes. If the telehealth platform won't tell you who your prescriber is before you pay, that's a red flag.

A qualified provider will:

Ask about your full medical history, including family history of thyroid cancer or pancreatitis
Review your current medications for interactions (especially insulin, sulfonylureas, or oral contraceptives)
Order baseline labs (at minimum: HbA1c, lipid panel, kidney function, liver function)
Discuss contraindications — personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), or a history of pancreatitis
Provide a written titration schedule with specific dose escalation timelines

Red Flags to Watch For

No medical intake or history review. If you can get a prescription by filling out a three-question form and entering your credit card, run. A proper evaluation should take 15-30 minutes minimum, even via telehealth.

Guaranteed results. No legitimate provider will guarantee you'll lose a specific amount of weight. Clinical trials show average weight loss of 15-22% of body weight with semaglutide and tirzepatide, but individual variation is massive. Anyone promising "30 pounds in 30 days" is selling you a fantasy.

No mention of side effects. GI side effects affect roughly 40-50% of patients during dose escalation. If your provider doesn't discuss nausea, vomiting, diarrhea, and constipation as normal possibilities, they're not being transparent.

Pressure to skip titration. Dose titration exists for a reason — it reduces side effects and lets your body adjust. Starting at the full therapeutic dose is dangerous. The standard semaglutide titration takes 16-20 weeks. Tirzepatide takes 20-32 weeks. Anyone pushing you to a high dose fast is prioritizing speed over safety.

Cash-only, no documentation. Legitimate providers maintain medical records and can send them to other physicians. If they can't or won't provide documentation of your treatment, you're in a gray area.

Telehealth-Specific Checks

The telehealth GLP-1 space is where most of the problems concentrate. Before signing up for any online program:

Verify the platform operates in your state (telehealth licensing varies by state)
Confirm they use a HIPAA-compliant platform for consultations
Check if they have a process for handling emergencies or adverse reactions
Ask whether your prescriber will be the same person at each follow-up or if you'll see a rotating cast
Read their cancellation and refund policies — some platforms lock you into subscriptions

Red Flags in the Medication Itself: Brand-Name vs. Compounded

Not all GLP-1 medications are created equal. The gap between FDA-approved brand-name medications and compounded versions is one of the biggest safety variables in 2026. For a deep dive on this topic, see our full comparison of compounded vs. brand-name GLP-1 medications.

Brand-Name Medications: What to Verify

Brand-name medications like Wegovy, Ozempic, Zepbound, and Mounjaro come from FDA-inspected manufacturing facilities with rigorous quality control. That doesn't mean you should accept them blindly.

Check the packaging. Authentic GLP-1 pens come in sealed, tamper-evident packaging with lot numbers, expiration dates, and manufacturer information. Counterfeit medications exist — particularly from overseas sources. If the packaging looks off, the labeling is in a foreign language, or there's no lot number, don't use it.

Verify the pharmacy. Brand-name GLP-1s should come from a licensed US pharmacy (retail or mail-order). Check that the pharmacy is licensed in your state through your state board of pharmacy. Major mail-order pharmacies like CVS Caremark, Express Scripts, or OptumRx are generally safe bets.

Inspect the medication. Semaglutide and tirzepatide solutions should be clear and colorless. If the liquid is cloudy, discolored, or contains particles, do not inject it. Check the expiration date. Once in use, most GLP-1 pens are good for 28-56 days depending on the product — check the package insert for the specific medication.

Compounded Medications: Higher Risk, More Verification Needed

Compounded GLP-1 medications became enormously popular during the 2023-2025 shortage period. They remain available in 2026, though the regulatory landscape has shifted significantly.

The numbers tell the story. By September 2025, the FDA had received approximately 520 adverse event reports related to compounded semaglutide and 480 reports related to compounded tirzepatide — over 1,000 total, including reports of hospitalizations and deaths. Many of these were linked to dosing errors, contamination, or incorrect formulations.

If you're using a compounded GLP-1, verify:

The compounding pharmacy is 503B-registered with the FDA — these pharmacies follow current Good Manufacturing Practices (cGMP) and are subject to FDA inspection. 503A pharmacies (traditional compounding pharmacies filling individual prescriptions) have less oversight.
The pharmacy provides a Certificate of Analysis (COA) for each batch, confirming the active ingredient identity, potency, sterility, and endotoxin levels. If they can't provide this, find a different pharmacy.
The concentration matches your prescription. Dosing errors are one of the most common problems with compounded GLP-1s. Compounded semaglutide often comes in multi-dose vials at various concentrations (e.g., 2mg/mL, 5mg/mL). Make sure you understand exactly how many units to draw for your prescribed dose.
The product does not contain suspicious additives. The FDA announced plans to restrict certain ingredients used in mass-marketed compounded GLP-1s — particularly combinations with vitamin B12, L-carnitine, or other "proprietary blends" that have no clinical evidence supporting their addition and may create safety risks.
Storage conditions are met. Compounded semaglutide requires refrigeration (36-46°F). If it shipped without cold packing or arrived warm, do not use it.

The Salt Form Matters

A technical but critical point: FDA-approved semaglutide uses the base form of the molecule. Many compounding pharmacies use semaglutide sodium salt, which is a different chemical entity. The FDA has stated that compounded semaglutide sodium salt is not a copy of an approved drug. This distinction matters for both efficacy and safety. Ask your compounding pharmacy which form they use and discuss this with your prescriber.

The Pre-Treatment Safety Checklist: 12 Items to Complete Before Your First Dose

Before your first injection, work through this checklist with your provider. Print it out. Bring it to your appointment. Don't let anything slide.

Medical History and Screening

Complete medical history reviewed — including all current medications, supplements, past surgeries, and chronic conditions. GLP-1 medications interact with insulin, sulfonylureas, and medications that depend on gastric emptying for absorption.
Family history of thyroid cancer assessed — GLP-1 receptor agonists carry a boxed warning about thyroid C-cell tumors based on animal studies. Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 is an absolute contraindication.
History of pancreatitis documented — patients with a history of pancreatitis should use GLP-1s with extreme caution. Your provider should discuss this risk explicitly.
Baseline labs ordered and reviewed — at minimum: HbA1c (even if you don't have diabetes), comprehensive metabolic panel (kidney and liver function), lipid panel, and thyroid function. Some providers also order a baseline amylase/lipase to monitor for pancreatic inflammation.

Treatment Plan

Written titration schedule provided — you should have a document showing your starting dose, escalation timeline, and target maintenance dose. For semaglutide, this typically means starting at 0.25mg weekly for 4 weeks, then 0.5mg for 4 weeks, and escalating through 1mg, 1.7mg, and 2.4mg. For tirzepatide, the starting dose is 2.5mg weekly for 4 weeks, escalating through 5mg, 7.5mg, 10mg, 12.5mg, and 15mg.
Follow-up schedule established — you should have appointments scheduled (even virtual) at 4 weeks, 8 weeks, 12 weeks, and then every 3 months minimum. More frequent check-ins during dose escalation are better.
Side effect management plan discussed — your provider should explain what to do about nausea (eat smaller meals, avoid high-fat foods, stay hydrated), constipation (fiber, hydration, possibly a stool softener), and when to call them vs. when to go to the ER.

Practical Preparation

Injection technique demonstrated — if you're using a pen, your provider or pharmacist should walk you through it. If you're using a vial and syringe (common with compounded products), this training is even more critical — drawing the wrong amount is one of the top causes of adverse events.
Storage requirements understood — most GLP-1 pens need refrigeration before first use and can be kept at room temperature (up to 86°F) for a limited time after. Compounded vials always need refrigeration.
Emergency contacts established — know how to reach your provider after hours. Know when to call 911 (severe abdominal pain, signs of allergic reaction, difficulty breathing).
Upcoming procedures flagged — the FDA now requires safety information about the risk of pulmonary aspiration on all GLP-1 receptor agonist labels. If you have any surgery, endoscopy, or procedure requiring sedation planned, inform both your prescriber and the anesthesiologist. Current guidance suggests stopping GLP-1s at least 1-3 weeks before procedures involving sedation, but discuss the specific timeline with your anesthesiologist.
Nutritional counseling discussed — GLP-1 medications suppress appetite significantly. Without nutritional guidance, patients risk inadequate protein intake, which accelerates muscle loss. A target of 1.0-1.2g of protein per kg of body weight per day is commonly recommended. Ask your provider about whether a dietitian referral makes sense.

During Treatment: Warning Signs That Demand Immediate Attention

Once you're on a GLP-1 medication, most side effects are mild and expected. Nausea affects roughly 40-50% of patients during dose escalation. Constipation, diarrhea, and mild abdominal discomfort are common. These typically improve within 2-4 weeks at each dose level.

But some symptoms are not normal and require immediate medical attention. Here's how to tell the difference.

Mild Side Effects (Expected, Manageable)

These are part of the normal adjustment process and usually respond to lifestyle modifications:

Nausea without vomiting — eat smaller meals, avoid greasy food, try ginger or peppermint tea
Mild constipation — increase water intake, add fiber, consider a stool softener
Decreased appetite — expected and part of how the medication works, but make sure you're still eating enough protein
Mild fatigue — especially during the first 1-2 weeks at a new dose
Mild injection site reactions — redness, swelling, or itching at the injection site that resolves within a day or two
Mild acid reflux — eating smaller meals and avoiding lying down after eating usually helps

Serious Side Effects (Call Your Doctor Immediately)

These symptoms could indicate a dangerous complication and should never be ignored:

Severe, persistent abdominal pain — especially if it radiates to your back. This could indicate pancreatitis. Acute pancreatitis has been reported in clinical trials at a rate of approximately 0.1-0.3% of patients, but it's a medical emergency when it occurs.
Persistent vomiting (more than 24 hours) — this can cause dehydration, electrolyte imbalances, and in patients with diabetes, acute kidney injury. If you can't keep fluids down for a full day, seek medical care.
Signs of gallbladder problems — severe upper right abdominal pain, pain between your shoulder blades, or nausea with fever. GLP-1 medications are associated with an increased risk of gallbladder-related events, including cholelithiasis (gallstones) and cholecystitis.
Signs of allergic reaction — swelling of the face, lips, tongue, or throat; difficulty breathing; severe rash or hives. These are rare but require emergency treatment.
Symptoms of hypoglycemia — shakiness, sweating, confusion, rapid heartbeat. This is most common in patients also taking insulin or sulfonylureas. If you're on these combination therapies, discuss glucose monitoring with your provider.
Vision changes — blurred vision or sudden visual changes in patients with diabetes. FDA data has associated GLP-1 use in type 2 diabetes with increased reports of retinopathies, particularly in patients who experience rapid blood sugar reduction.
Kidney problems — decreased urination, swelling in legs or ankles, unusual fatigue. Dehydration from GI side effects can trigger or worsen kidney issues, especially in patients with pre-existing kidney disease.
Unusual mood changes — while the FDA's comprehensive review of 91 placebo-controlled trials involving 107,910 patients found no overall increased risk of psychiatric adverse events with GLP-1s, and the agency has requested removal of suicidal ideation warnings, individual patients should still report significant mood changes, depression, or anxiety to their provider.

The 48-Hour Rule

If you experience any GI side effect that doesn't improve within 48 hours, contact your provider. If a side effect is severe enough that it interferes with your ability to eat, drink water, or go about your normal daily activities, don't wait 48 hours — call the same day.

Monitoring Schedule During Treatment

Even when things are going well, ongoing monitoring matters:

Every 4 weeks during dose escalation: Check in with your provider (even a brief telehealth visit). Report any side effects. Discuss whether to continue escalating or hold at the current dose.
Every 3 months once at maintenance dose: Labs (HbA1c if diabetic, kidney function, lipid panel), weight and body composition tracking, review of nutritional intake.
Every 6 months: Comprehensive check-in including assessment of continued need, discussion of muscle mass preservation, and review of any new medications or health conditions.
Annually: Full metabolic panel, thyroid function tests, and discussion about long-term treatment plan.

Compounded GLP-1 Safety: A Dedicated Checklist

Because compounded GLP-1 medications carry distinct risks that brand-name products don't, they deserve their own section. If you're using or considering a compounded version, work through every item below.

The Pharmacy Verification Checklist

Is the pharmacy a 503B outsourcing facility? — check the FDA's registered outsourcing facilities list. 503B facilities must follow cGMP standards and submit to FDA inspections.
Can the pharmacy provide a Certificate of Analysis (COA) for your specific batch? — a COA should confirm potency (is the concentration what it claims?), sterility (tested for bacterial/fungal contamination), endotoxin levels (below safe thresholds), and pH.
Does the pharmacy have a track record? — search the FDA's warning letters database for any enforcement actions. Search "[pharmacy name] FDA warning letter" to check.
Is the pharmacy located in the US? — do not use compounded GLP-1s from overseas pharmacies. Period. You have no recourse if something goes wrong, and quality standards vary enormously.
Does the pharmacy have a pharmacist available to answer your questions? — a legitimate compounding pharmacy will have a licensed pharmacist who can explain the formulation, discuss stability data, and answer dosing questions.

The Product Verification Checklist

Does the label include the correct drug name, concentration, lot number, and expiration date? — missing any of these is a disqualifying red flag.
Is the concentration appropriate for your dose? — common compounded semaglutide concentrations are 1mg/mL, 2mg/mL, and 5mg/mL. If your prescribed dose is 0.25mg and your vial is 5mg/mL, you're drawing 0.05mL (5 units on an insulin syringe). Errors here are extremely common and extremely dangerous.
Does the product look right? — clear, colorless solution. No particles, cloudiness, or discoloration. No cracked vials or missing seals.
Was it shipped with cold packing? — compounded semaglutide must be refrigerated. It should arrive cold. If it didn't, contact the pharmacy before using it.
Does the label list all ingredients? — be wary of "proprietary blend" formulations. You should know exactly what's in your injection. The FDA has moved to restrict certain additive ingredients in mass-marketed compounded GLP-1s.

Dosing Safety for Compounded Vials

Drawing medication from a vial is more error-prone than using a pre-filled pen. The most common mistakes:

Using the wrong syringe type. Insulin syringes measure in "units," and 1 unit = 0.01mL. If your compounded semaglutide is 5mg/mL and your dose is 0.5mg, you need 0.1mL = 10 units on an insulin syringe. Double-check this math with your pharmacist.
Confusing mg and mL. If someone tells you to "take 0.5" without specifying the unit, clarify. 0.5mg and 0.5mL are vastly different amounts depending on the concentration.
Reusing needles. Never reuse needles. Each injection = new needle.
Injecting air bubbles. Small air bubbles in a subcutaneous injection are not dangerous, but large air pockets can affect dose accuracy. Tap the syringe and push air out before injecting.

Surgical and Procedural Safety: The Aspiration Risk

This is one of the most important safety developments in 2026, and many patients still don't know about it.

The FDA now requires all GLP-1 receptor agonist labels to include safety information about the risk of pulmonary aspiration — the inhalation of food or stomach contents into the lungs during procedures that use anesthesia or deep sedation.

Why GLP-1s Increase This Risk

GLP-1 medications work partly by slowing gastric emptying — food stays in your stomach longer, which contributes to feeling full. But this same mechanism means that even after standard fasting before surgery (typically nothing after midnight the night before), your stomach may still contain food. If you vomit or regurgitate during sedation, that material can enter your lungs, causing aspiration pneumonia or worse.

This isn't theoretical. Case reports and the FDA's adverse event database have documented instances of aspiration in GLP-1 patients undergoing routine procedures like colonoscopies, upper endoscopies, and surgeries under general anesthesia.

What You Should Do

Tell every healthcare provider — your surgeon, anesthesiologist, gastroenterologist, dentist (if sedation is involved), and anyone else performing a procedure. Don't assume they'll check your medication list.
Discuss timing — current guidance from the American Society of Anesthesiologists suggests holding GLP-1 medications for at least one week before elective procedures. Some experts recommend 2-3 weeks, especially at higher doses. There's no universal consensus yet, so discuss the specifics with your anesthesiologist.
Extended fasting may be recommended — your anesthesiologist may ask you to start a liquid diet 24-48 hours before the procedure and fast longer than the standard overnight period.
Gastric ultrasound — some anesthesiologists now perform a point-of-care gastric ultrasound before sedation to check whether the stomach is empty. Ask whether this is available at your facility.
Don't stop your medication without guidance. Abruptly stopping a GLP-1 can cause rebound appetite and blood sugar spikes in diabetic patients. Your provider should manage the timing of your last dose.

Procedures That Require This Conversation

Any procedure involving:

General anesthesia
Deep sedation (propofol sedation for colonoscopy, for example)
Moderate sedation (conscious sedation)
Emergency surgery (inform the anesthesiologist you're on a GLP-1 immediately)

Even dental procedures with IV sedation qualify. Don't overlook this.

Long-Term Safety Monitoring: What the Research Shows

GLP-1 medications have been on the market for nearly two decades (exenatide was approved in 2005), but the newer, more potent formulations used for weight loss — particularly high-dose semaglutide and tirzepatide — have a shorter track record at the doses now commonly prescribed.

Here's what we know, what we're still learning, and what to monitor long-term.

What the Data Shows So Far

Cardiovascular benefits are real. The SELECT trial demonstrated that semaglutide 2.4mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with overweight/obesity and established cardiovascular disease but without diabetes. This is one of the strongest safety signals in favor of GLP-1s.

GI side effects are the most common reason for discontinuation. Across phase 3 trials, roughly 5-10% of patients discontinued semaglutide or tirzepatide due to GI side effects. This is significantly higher than placebo groups but lower than early media reports suggested.

Cancer risk is being monitored. The thyroid C-cell tumor warning is based on animal studies. Human epidemiological data have not confirmed an increased risk of thyroid cancer, but the monitoring period for this rare cancer type needs to be longer before definitive conclusions can be drawn. The FDA data analysis also flagged increased reporting of pancreatic neoplasms in GLP-1 users with type 2 diabetes compared to other drug classes. This signal requires continued surveillance.

Muscle loss is a legitimate concern. Rapid weight loss from any cause — including GLP-1 medications — results in loss of both fat and lean mass. Studies suggest that 25-40% of weight lost on GLP-1 medications may be lean mass without resistance training. This is why strength training and adequate protein intake are critical during treatment.

Bone density effects are under study. Some research suggests that rapid weight loss may be associated with decreased bone mineral density, though it's not clear whether GLP-1 medications contribute to this independently of the weight loss itself. Long-term bone density monitoring (DEXA scans) may be warranted for patients on prolonged treatment.

The FDA's Ongoing Surveillance

FDA data analysis comparing GLP-1 users to patients on other drug classes (DPP-4 inhibitors and SGLT2 inhibitors) identified several signals that warrant attention:

In weight control/obesity populations:

Increased reports of general nutritional disorders
Sensory abnormalities
Panic attacks and panic disorders
Depressive disorders
Eating disorders
Immune-associated conditions

In type 2 diabetes populations:

Retinopathies (vision changes related to rapid blood sugar reduction)
Skin and subcutaneous conditions
Hearing losses
Cataracts

Across both populations:

Alopecia (hair loss)
Taste disorders
Gastrointestinal pain

These are signal detections from adverse event reporting databases, not confirmed causal relationships. But they inform what you and your provider should be watching for during long-term treatment. If you're comparing specific medications, our semaglutide vs. tirzepatide breakdown covers the differences in side effect profiles between the two leading drugs.

What to Monitor Long-Term

If you're planning to stay on a GLP-1 medication for the long haul (and current evidence suggests many patients will need to), here's what your provider should be tracking:

Body composition — not just weight on the scale, but lean mass vs. fat mass. Ask about body composition scans (DEXA, bioimpedance) every 6-12 months.
Nutritional status — protein intake, vitamin and mineral levels. Reduced food intake means reduced micronutrient intake. Consider a comprehensive nutritional panel annually.
Kidney function — especially if you've experienced significant dehydration from GI side effects.
Thyroid function — annual thyroid panel, and report any neck lumps, hoarseness, or difficulty swallowing immediately.
Mental health — track mood, anxiety levels, and your relationship with food. Some patients develop disordered eating patterns when their appetite suppression is very strong.
Hair and skin health — alopecia and skin changes are among the signals identified in FDA surveillance data. Report significant hair loss or skin changes.
Bone density — consider a baseline DEXA scan, especially for postmenopausal women or patients with risk factors for osteoporosis.

Frequently Asked Questions

How do I know if my compounded GLP-1 medication is safe?

Verify that your compounding pharmacy is a 503B-registered outsourcing facility with the FDA, request a Certificate of Analysis (COA) for your specific batch, confirm the product is clear and colorless with proper labeling including concentration, lot number, and expiration date, and ensure it was shipped with cold packaging. The FDA received over 1,150 adverse event reports tied to compounded GLP-1s by late 2025, many related to dosing errors and contamination, so these verification steps are not optional.

Should I stop my GLP-1 medication before surgery?

Yes, but not without your provider's guidance. The FDA now requires pulmonary aspiration warnings on all GLP-1 receptor agonist labels because these medications slow gastric emptying, which means food may remain in your stomach longer than expected even after standard pre-surgical fasting. The American Society of Anesthesiologists suggests holding GLP-1 medications for at least one week before elective procedures, though some experts recommend 2-3 weeks at higher doses. Coordinate the timing with both your prescriber and your anesthesiologist.

What are the most dangerous side effects of GLP-1 medications?

The most serious adverse effects include acute pancreatitis (severe abdominal pain radiating to the back), gallbladder disease (upper right abdominal pain with fever), severe allergic reactions (swelling of face, lips, or throat), and acute kidney injury from dehydration caused by persistent vomiting. While these are rare — pancreatitis occurs in approximately 0.1-0.3% of patients in clinical trials — they are medical emergencies requiring immediate treatment. Most patients experience only mild to moderate GI side effects that resolve with time.

Did the FDA find a link between GLP-1 medications and suicidal thoughts?

No. The FDA completed a comprehensive evaluation including a meta-analysis of 91 placebo-controlled trials involving 107,910 patients and found no evidence of increased suicidal behavior or ideation with GLP-1 receptor agonists. Based on these findings, the FDA has requested the removal of suicidal behavior and ideation warnings from GLP-1 medication labels, including semaglutide, tirzepatide, and liraglutide. However, any significant mood changes during treatment should still be reported to your provider.

How much muscle loss should I expect on a GLP-1 medication?

Without countermeasures, research suggests that 25-40% of total weight lost on GLP-1 medications may come from lean mass rather than fat. This is consistent with any form of calorie restriction and rapid weight loss, not unique to GLP-1s. The best defense is a combination of resistance training (at minimum 2-3 sessions per week) and adequate protein intake (1.0-1.2g per kg of body weight per day). Discuss a strength training plan and nutritional targets with your provider before starting treatment.